Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Alx Oncology Holdings (ALXO) Return on Equity (2020 - 2023)

Alx Oncology Holdings' Return on Equity history spans 4 years, with the latest figure at 0.77% for Q3 2023.

  • For Q3 2023, Return on Equity fell 54.0% year-over-year to 0.77%; the TTM value through Sep 2023 reached 0.77%, down 54.0%, while the annual FY2022 figure was 0.04%, 4.0% up from the prior year.
  • Return on Equity for Q3 2023 was 0.77% at Alx Oncology Holdings, down from 0.58% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.25% in Q2 2020 and bottomed at 0.77% in Q3 2023.
  • The 4-year median for Return on Equity is 0.16% (2021), against an average of 0.22%.
  • The largest annual shift saw Return on Equity increased 16bps in 2021 before it crashed -54bps in 2023.
  • A 4-year view of Return on Equity shows it stood at 0.11% in 2020, then grew by 23bps to 0.08% in 2021, then plummeted by -449bps to 0.45% in 2022, then crashed by -71bps to 0.77% in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Return on Equity are 0.77% (Q3 2023), 0.58% (Q2 2023), and 0.51% (Q1 2023).